Kodiak Sciences Inc
(FRA:K27)
€
3.546
0.072 (2.07%)
Market Cap: 211.94 Mil
Enterprise Value: 80.00 Mil
PE Ratio: 0
PB Ratio: 0.96
GF Score: 37/100 Kodiak Sciences Inc at Goldman Sachs Healthcare Conference Transcript
Jun 14, 2023 / 11:40PM GMT
Release Date Price:
€8.66
(+4.82%)
Andrea R. Tan
Goldman Sachs Group, Inc., Research Division - Research Analyst
Thanks, everyone, for joining us for the last session of the third day of our conference. I'm pleased to be joined by Victor Perlroth, CEO of Kodiak Sciences. Thank you so much, Victor.
Victor Perlroth
Kodiak Sciences Inc. - Co-Founder, Chairman, CEO & President
Thanks a lot, Andrea. Can you hear me?
Questions & Answers
Andrea R. Tan
Goldman Sachs Group, Inc., Research Division - Research Analyst
Yes. So maybe we can start. We're at an exciting time for Kodiak. We're sitting in front of 4 Phase III trials that are coming, starting in July. Maybe help frame -- maybe let's take a step back actually. Let's talk about your antibody platform, and how is it uniquely positioned to address this idea of durability?
Victor Perlroth
Kodiak Sciences Inc. - Co-Founder, Chairman, CEO & President
Right. Well, that's a good question because we start with the science of the design and then
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot